← Browse by Condition
Medical Condition
relapsed multiple myeloma
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2, Phase 4
NCT06348108 Phase 1
Recruiting
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Enrollment
32 pts
Location
United States
Sponsor
Alfred Chung, MD
NCT05896228 Phase 2
Recruiting
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment
30 pts
Location
United States
Sponsor
Benjamin T Diamond, MD
NCT07094048 Phase 4
Recruiting
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Enrollment
80 pts
Location
Canada
Sponsor
CHU de Quebec-Universite Laval